GRP Antibody

1. A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC. PMID: 29729229
2. Pro-GRP is sensitive for SCLC diagnosis. Since high marker levels are related to high disease burden, pro-GRP may have a negative prognostic significance. Follow-up studies are required to define its role in clinical practice in monitoring responses to treatment and early relapses PMID: 28967066
3. Altogether, these data show that humanized anti-progastrin antibodies might represent a potential new treatment for K-RAS-mutated colorectal patients, for which there is a crucial unmet medical need PMID: 28600477
4. Both TRPV1 and GRP are implied in midbrain physiology of importance to neurological and neuropsychiatric disorders. PMID: 27762319
5. GRP/GRP-R signaling activation contributes to castration-resistant prostate cancer progression PMID: 27542219
6. progastrin expression may be predictive of aggressive tumour behaviour in patients with colorectal cancer. PMID: 28432443
7. Thus the combination of favourable in vitro and in vivo properties renders BA1 as more potential antagonist bombesin-peptide for targeting GRP-receptor positive tumor. These properties are encouraging to carry out further experiments for non-invasive receptor targeting potential diagnostinc and therapeutic agent for tumors. PMID: 28088445
8. serum level not a biomarker in small cell lung cancer PMID: 29145241
9. pro-gastrin releasing peptide has a role in promoting the cell proliferation and progression in small cell lung cancer PMID: 27639644
10. Our results suggest that, similar to what happens in neutrophils, gastrin-releasing peptide is a migratory, rather than a proliferative, stimulus, for non-small cell lung carcinoma cells, indicating a putative role for gastrin-releasing peptide and gastrin-releasing peptide receptor in metastasis PMID: 28351312
11. Serum Pro-GRP was promising biomarker for SCLC diagnosis. PMID: 28230031
12. High proGRP expression is associated with poor response to chemotherapy in small cell lung cancer. PMID: 26886220
13. CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer PMID: 26560853
14. Data show that serum neuron-specific enolase, cytokeratin 19 fragment 21-1, pro-gastrin-releasing peptide, squamous cell carcinoma antigen, tissue inhibitor of metalloproteinase-1, and human epididymis protein 4 are not associated with brain metastases. PMID: 26730601
15. Our results suggest that progastrin inhibits the acquisition of a M2-phenotype in human macrophages. PMID: 24901518
16. No association of 16 GRP and 7 GRPR variants were found with agoraphobia with/without panic disorder. PMID: 24912045
17. the role of autophagy in the degradation of gastrin-releasing peptide and subsequent inhibition of angiogenesis PMID: 24108003
18. High serum proGRP levels are associated with small-cell lung cancer. PMID: 24375395
19. The Gastrin-releasing peptide(GRP)triggers the growth of HepG2 cells through blocking the ER stress-mediated pathway. PMID: 23379566
20. GRP silencing decreases anchorage-independent growth, inhibits cell migration and neuroblastoma cell-mediated angiogenesis. PMID: 24039782
21. GRP-expressing C and A delta fibers that coexpress SP or CGRP makes these neurons pruriceptors. PMID: 23615431
22. The levels of GRP were upregulated in cells treated with HGF in a dose-dependent manner. HGF-induced expression of Ets-1 and IL-8 was increased more by GRP treatment. PMID: 23924923
23. inhibits the process of autophagy in vascular endothelial cells, thereby increasing endothelial cell proliferation and tubule formation PMID: 23608754
24. GRP serum level is higher in patients with pruritus in patients with atopic dermatitis. PMID: 23353988
25. Tonic stretch of human myometrium increases contractility and stimulates the expression of a known smooth muscle stimulatory agonist, GRP. GRP receptor antagonists attenuate the effect of stretch. PMID: 22411014
26. Data indicate that progastrin-releasing peptide (proGRP) assays with both time-resolved immunofluorometric assay (TR-IFMA) and Advanced Life Science Institute (ALSI) ELISA showed good clinical validity. PMID: 22399443
27. Percent changes in serum ProGRP showed better correlation to the sum of the tumor diameters (SOD) and prognostic impact than that of NSE. PMID: 22300752
28. Results describe the mRNA expression of CRABP1, RERG, and GRP in pituitary adenomas. PMID: 21270509
29. nonamidated peptides derived from the C terminus of pro-GRP are expressed in significant quantities in colorectal cancer cell lines PMID: 22202166
30. proGRP is a complementary tumour marker for prognosis and treatment monitoring in patients with neuroendocrine tumour PMID: 21415235
31. serum-positive non-small-cell lung cancers may have neuroendocrine differentiation PMID: 21529988
32. Progastrin-releasing peptide cab be used as a marker for quality control in clinical sample processing and storage. PMID: 22261454
33. Abrogating GRP/GRPR signaling specifically down-regulates HP1(Hsbeta) expression and inhibiting GRPR signaling, or ablating HP1(Hsbeta) expression, increases colon cancer cell invasiveness in vitro. PMID: 21281799
34. Gastrin-releasing peptide is elevated in prostate neoplasm patients undergoing androgen deprivation therapy and may be involved in the initiation of hormonal escape prostate neoplasms. PMID: 20945407
35. GRP promotes the growth of HepG2 cells through interaction with GRPR co-expressed in tumor cells, and subsequently activates MAPK/ERK1/2 via EGFR-independent mechanisms. PMID: 20596631
36. Data indicate that various serum proGRP fragments are promising tools for future investigations on the relationship between fragment distribution and diagnosis and prognosis. PMID: 19907206
37. GRP/GRP-R play a transient and non-critical role in intestinal development PMID: 11960700
38. mRNA transcripts are expressed in tumor cells of patients with small cell lung cancer PMID: 12474049
39. ProGRP is a valuable tumour marker for the detection and monitoring of small cell lung cancer (SCLC) and a good tool for discriminating non-small cell lung cancer (NSCLC) versus SCLC PMID: 12820318
40. results show that Pro-GRP may be a potential tumor marker for small cell lung carcinoma PMID: 12820319
41. Mitogenic effects of GRP in head and neck squamous cells are mediated by activation of the epidermal growth factor receptor. PMID: 13679857
42. GRP is over-expressed in esophageal squamous cell carcinoma, and its over-expression may play a role in such carcinoma development and growth PMID: 14764456
43. Measuring serum levels in lung cancer patients may be useful in drug therapy monitoring. PMID: 15638385
44. GRP is a new angiogenic peptide and that its inhibition offers an attractive tool to reduce tumor burden. PMID: 15750618
45. An increase in GRP binding capacity, as a result of GRP-R overexpression, down-regulates PTEN expression. Inhibition of the tumor suppressor gene PTEN may be an important regulatory mechanism involved in GRP-induced cell proliferation in neuroblastomas. PMID: 15849504
46. BN/GRP and substance P are involved together with cytokines in the neuroimmunomodulation that occurs in the arthritic joint. PMID: 15899028
47. results show that TACE undergoes phosphorylation that regulates release of amphiregulin upon GRP treatment; a signaling cascade of GRP-Src-PI3-K-PDK1-TACE-amphiregulin-EGFR with multiple points of interaction, translocation & phosphorylation is suggested PMID: 16641105
48. First evidence is provided that the calcium-ion/calcineurin/NFAT-linked pathway is involved in bombesin-mediated induction of Cox-2, a gene that promotes colon carcinoma invasiveness. PMID: 16909108
49. GRP upregulation of ICAM-1 via FAK promotes tumor cell motility and attachment to the extracellular matrix. PMID: 16920698
50. BN/GRP is produced by non-neuronal cells in the synovial tissue in rheumatoid and osteoarthritis PMID: 18289674

显示更多

收起更多

HGNC: 4605

OMIM: 137260

KEGG: hsa:2922

STRING: 9606.ENSP00000256857

UniGene: Hs.153444